Skip to main content

Amevive Side Effects

Generic name: alefacept

Medically reviewed by Last updated on Jun 4, 2023.

Note: This document contains side effect information about alefacept. Some dosage forms listed on this page may not apply to the brand name Amevive.

Applies to alefacept: intramuscular powder for solution.

Serious side effects of Amevive

Along with its needed effects, alefacept (the active ingredient contained in Amevive) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking alefacept:

More common

Less common


Other side effects of Amevive

Some side effects of alefacept may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common


For Healthcare Professionals

Applies to alefacept: intramuscular powder for injection, intravenous powder for injection.


Immunologic side effects including dose-dependent reductions in circulating CD4+ and CD8+ T lymphocyte counts have been reported.[Ref]


Cardiovascular side effects including coronary artery disorder (<1%) and myocardial infarction (<1%) have been the adverse reactions which most commonly resulted in clinical intervention.[Ref]

The total percentage of alefacept-treated patients hospitalized for cardiovascular events was 1.2%.[Ref]


Oncologic side effects including malignancies have been reported. Postmarketing reports of malignancies including skin, solid organ, lymphomas and leukemias have also been received.[Ref]

Twenty five of the 1,357 patients who received alefacept were diagnosed with a total of 35 treatment-emergent malignancies. Six cases were basal cell and seventeen cases were squamous cell cancers of the skin. Three cases of lymphoma have been reported; one was classified as non-Hodgkin's follicle-center cell lymphoma and two were classified as Hodgkin's disease.[Ref]


General side effects including chills (6%), dizziness, headache, and accidental injury have been reported. Postmarketing reports of sepsis and opportunistic infections (viral, fungal, and bacterial) have been received.[Ref]

Chills have been reported to occur predominantly with intravenous administration.[Ref]


Local side effects including injection site pain and injection site inflammation have been reported.[Ref]


Gastrointestinal side effects including nausea have been reported. Postmarketing reports of clostridium difficile colitis have been received.[Ref]


Respiratory side effects including pharyngitis and increased cough have been reported. Postmarketing reports of pharyngitis have also been received.[Ref]


Dermatologic side effects including pruritus have been reported. Postmarketing reports of cellulitis have been received.[Ref]


Musculoskeletal side effects including myalgia have been reported.[Ref]


Hepatic side effects including postmarketing reports of asymptomatic transaminase elevation, fatty infiltration of the liver, hepatitis, and severe liver failure have been received.


Genitourinary side effects including postmarketing reports of urinary tract infection have been received.


1. Product Information. Amevive (alefacept). Biogen. 2003.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.